Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  (MRC DTP) Understanding the association between response to treatment, psychosocial factors and multi-morbidity on patient reported outcomes in people with rheumatoid arthritis


   Faculty of Biology, Medicine and Health

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr S Verstappen, Dr James Gwinnutt, Prof K Hyrich  No more applications being accepted  Competition Funded PhD Project (Students Worldwide)

About the Project

Rheumatoid arthritis (RA) is a chronic autoimmune disease. Although more effective therapies are available now compared to 20 years ago, the disease still has a huge impact on patients’ daily lives.  Whilst disease activity is often well controlled, this does not always translate into improvements in patient reported outcomes (PROs), such as quality of life, function, physical activity and work participation – this is potentially due to the multifaceted causal pathway from RA to PRO severity, with many psychological, socioeconomic and treatment related factors potentially contributing. In addition, patients with RA are more likely to develop other morbidities (e.g. cardiovascular, lung disorders) which may impact on PROs. Many clinical trials include PROs as part of their assessment schedule, and PROs are nowadays considered important outcomes, not only by patients with RA and health professionals, but also by the National Institute for Health and Care Excellence (NICE, UK) and the Food and Drug Administration (FDA, USA). Given this current interest, it is important for policy makers, health professionals and people with RA to understand precisely how PROs develop over time in RA and what factors are important in determining the severity of these PROs (e.g. treatment response, psychosocial factors, multi-morbidity). 

 This PhD project will aim to understand the interplay between treatment response, psychosocial factors and multi-morbidity on important PROs in patients with early and established RA. By understanding the independent contribution of these factors on PROs, targeted disease management and thus quality of life can be improved. 

 The PhD studentship is especially suitable for candidates with an MSc in Psychology, MSc in Epidemiology, MSc applied medical statistics or MSc in Social Science. 

http://www.cfe.manchester.ac.uk/

Entry Requirements

Applicants must have obtained or be about to obtain a First or Upper Second class UK honours degree, or the equivalent qualifications gained outside the UK, in an appropriate area of science, engineering or technology.

How to Apply

To be considered for this project you MUST submit a formal online application form - full details on how to apply can be found on the MRC Doctoral Training Partnership (DTP) website www.manchester.ac.uk/mrcdtpstudentships 

Applicants interested in this project should make direct contact with the Primary Supervisor to arrange to discuss the project further as soon as possible.

Equality, Diversity and Inclusion

Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website https://www.bmh.manchester.ac.uk/study/research/apply/equality-diversity-inclusion/

Mathematics (25) Medicine (26)

Funding Notes

Funding will cover UK tuition fee and stipend only. The University of Manchester aims to support the most outstanding applicants from outside the UK. We are able to offer a limited number of scholarships that will enable full studentships to be awarded to international applicants. These full studentships will only be awarded to exceptional quality candidates, due to the competitive nature of this scheme.

References

1. Gwinnutt JM, Alsafar H, Hyrich KL, Lunt M, Barton A, Mm Verstappen S; RAMS co-investigators. Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy? Rheumatology, 2021 [Epub ahead].
2. Gwinnutt JM, Leggett S, Lunt M, Barton A, RAMS and BRAGGSS co-investigators, Hyrich KL, Walker-Bone K, Verstappen SMM. Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. Rheumatology, 2020;59:2908-2919.
3. Gwinnutt JM, Hyrich KL, RAMS Co-Investigators, Lunt M, Barton A, Verstappen SMM. Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as 'satisfactory'. Rheumatology, 2020 59(8): 1853-1861.
4. Shoop-Worrall SJW, Hyrich KL, Wedderburn LR, Thomson W, Geifman N; CAPS the CLUSTER Consortium. Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study. Lancet Rheumatol. 2020 Dec 4;3(2):e111-e121.
5. Pan Y, Norton S, Gwinnutt JM, Kearsley-Fleet L, Symmons DPM, Lunt M, Young A; BSRBR-RA Control Centre. Hyrich KL, Verstappen SMM. Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. PLoS One, 2019;14:e015999.